BioSpace News Archive

Rhythm Pharmaceuticals, Inc. announced that on February 2, 2024, the Compensation Committee of Rhythm’s board of directors granted inducement equity grants covering an aggregate of 20,295 shares of its common stock to six new employees, consisting of inducement stock options to purchase an aggregate of 13,530 shares of common stock and inducement restricted stock units, or RSUs, covering an aggregate of 6,765 shares of its common stock.

Intra-Cellular Therapies, Inc. today announced it will host a conference call and live webcast discussion at 8:30 a.m. Eastern Time on Thursday, February 22, 2024, to provide a corporate update and discuss details of the Company’s financial results for the quarter and year ended December 31, 2023.

Quoin Pharmaceuticals Ltd. today announced it has filed U.S. and International patent applications for a novel combination product as a potential treatment of Netherton Syndrome.

Sensus Healthcare, Inc. announces that the U.S. Patent and Trademark Office has issued Patent No. 11,894,123 B2, titled “Radiotherapy Mobile and Wireless Device Workflow Management System.”.

Madrigal Pharmaceuticals, Inc. today announced the publication of the pivotal Phase 3 MAESTRO-NASH trial of resmetirom in the New England Journal of Medicine.

Mineralys Therapeutics, Inc. today announced that it has entered into a securities purchase agreement with institutional accredited investors to sell securities in a private placement financing (the “PIPE”) for gross proceeds of approximately $120 million, before deducting estimated fees and expenses.

Palisade Bio, Inc. today announced the appointments of Bruce Sands, MD, MS and Florian Rieder, MD to its Clinical Advisory Board (CAB).

Veracyte, Inc. (Nasdaq: VCYT) announced today that it will release financial results for the fourth quarter and full-year 2023 after the close of market on Thursday, February 22, 2024.

Agilent Technologies Inc. announced that it has received two prestigious awards from SelectScience: Best New Drug Discovery & Development Product of 2023 and Drug Discovery & Development Webinar of the Year.

CUTERA, INC. (Nasdaq: CUTR), a leading provider of aesthetic and dermatology solutions, announced the international limited commercial release of AviClear, the first energy-based device FDA-cleared for the long-term treatment of mild, moderate, and severe acne.